Cargando…

Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort

INTRODUCTION: Vaccination plays a fundamental role in mastering the COVID‐19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenicity and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamani, Batool, Moradi Hasan‐Abad, Amin, Piroozmand, Ahmad, Dehghani, Mahsa, Arfaatabar, Maryam, Motedayyen, Hossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186999/ https://www.ncbi.nlm.nih.gov/pubmed/37249277 http://dx.doi.org/10.1002/iid3.858

Ejemplares similares

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
por: Greish, Khaled, et al.
Publicado: (2022)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: a case report
por: Vences, Miguel A., et al.
Publicado: (2022)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

SG-APSIC1049: Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults
por: Stoma, Igor, et al.
Publicado: (2023)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022)

Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
por: Stoma, Igor, et al.
Publicado: (2023)

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
por: Joudi, Maryam, et al.
Publicado: (2022)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
por: Chansaenroj, Jira, et al.
Publicado: (2022)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
por: Kaabi, Nawal Al, et al.
Publicado: (2022)

Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial
por: Ahi, Mohammadreza, et al.
Publicado: (2022)

Biochemical and histopathological evaluation of ChAdOx1-S and BBIBP-CorV vaccination in normal and streptozotocin-induced diabetic Wistar rats
por: Teymoorzadeh, Mahsa, et al.
Publicado: (2023)

The Effect of Disease Modifying Drugs of Multiple Sclerosis on the Effectiveness of BBIBP-CorV COVID19 Vaccine
por: Ghaffari, Mehran, et al.
Publicado: (2022)

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
por: Zhang, Yaowen, et al.
Publicado: (2022)

Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
por: Silva-Valencia, Javier, et al.
Publicado: (2023)

BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome
por: Shen, Yang, et al.
Publicado: (2023)

212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?
por: Javadinia, S.A., et al.
Publicado: (2022)

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
por: Wang, Hui, et al.
Publicado: (2020)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV
por: Babrukevich, Darya, et al.
Publicado: (2022)

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
por: Ferenci, Tamás, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jr0uvm2010eodfpurb3h0rlumr